AUPH vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AUPH exhibits mixed financial health with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, and no available Altman Z-Score limits distress risk assessment. The company shows robust profitability (ROE: 20.65%, Gross Margin: 80.16%) and strong recent earnings growth (YoY EPS +130%), yet trades above its Graham Number of $5.86 at a current price of $14.53, supported by a forward P/E of 15.54 that reflects growth optimism. Insider activity is bearish with recent selling, and technical trend is weak at 10/100, offsetting positive momentum from 1Y return of +81%. Analyst target of $16.67 suggests upside potential, but limited analyst coverage (6) and missing financial data constrain conviction.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AUPH vs LLY: Head-to-Head Comparison
This page compares Aurinia Pharmaceuticals Inc. (AUPH) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.